Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

2015 - TID 2015 Conference


This page contains exclusive content for the member of the following sections: TTS, TID

Transplant in the Tropics

3.3 - Leishmaniasis

Presenter: Wanessa T., Clemente, , Brazil
Authors: Wanessa T. Clemente

Overview

Leishmaniasis is a vector-bourne disease caused by Leishmania species, which may result in a heterogeneous group of illnesses, clinically divided in cutaneous and visceral forms. Worldwide, it presents an estimated frequency of 1.3 million new cases per year. Tropical and Mediterranean countries are considered endemic areas. Cutaneous Leishmaniasis (CL) incidence is greater than Visceral Leishmaniasis (VL), respectively one million cases/year and 0.2 to 0.4 million cases/year. On the other hand, in transplant recipients VL is the predominant form, with prevalence ranging from 0.1% to 0.5% in endemic countries. Infection occurs through the vector bite or can be transmitted by the transplanted organ or blood transfusion. Only one-third of the patients with VL exhibited the triad of fever, visceromegaly and cytopenia. CL is often similar to immunocompetent individuals but atypical features show parasite dissemination, clinical polymorphism and visceralisation. Combination of multiple methods is recommended for diagnosis. As the recommended treatment varies by species, species identification should be pursued. Treatment options are diverse and depend on patient feature, Leishmania specie, extension of disease, drug availability, concomitant infections or previous treatments. Immunosuppressants reduction and secondary prophylaxis may be recommended, but decisions must be individualized. Serologic screening of recipients or donors is not routinely done, but active disease should be ruled out.

Objectives

  1. Geography of Leishmaniasis
  2. Who and when to screen or monitor (donor and recipient)?
  3. Clinical presentation on transplant recipients
  4. Which test to use for diagnosis?
  5. What are the treatment options?
  6. Should prophylaxis be considered?

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Social

Contact

Staff Directory
+1-514-874-1717
This email address is being protected from spambots. You need JavaScript enabled to view it.

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada